Antiphospholipid antibodies: A new risk factor for restenosis after percutaneous transluminal coronary angioplasty?

Chiarugi Ludia, Prisco Domenico, Capanni Monia, Antonucci Emilia, Fedi Sandra, Alessandrello Liotta Agatina, Margheri Massimo, Giglioli Cristina, Dabizzi Roberto Piero, Simonetti Ignazio, Abbate Rosanna, Gensini Gian Franco

Research output: Contribution to journalArticlepeer-review


Antiphospholipid antibodies (aPL) have been found to be associated with arterial and venous thrombosis. Percutaneous transluminal coronary angioplasty (PTCA) is an established therapy for ischaemic heart disease (IHD), which is still affected by restenosis at a rate of 30-30%. This study was aimed at investigating the possible role of aPL in restenosis after PTCA. In sixty consecutive IHD patients, aPL (lupus anticoagulant -LA- and anticardiolipin antibodies -aCL) and markers of haemostatic activation were investigated before PTCA, and patients were followed up for restenosis. No infections, autoimmune disease or treatment by drugs that may alter aPL levels occurred in any of the patients. aPL were found in 15/60 patients: aCL in 7/60, LA in 5/60 and aCL and LA in 3/60. No statistically significant difference was found between aPL negative and aPL positive patients in pre PTCA plasma levels of prothrombin activation fragment (F1 + 2) 1.4 nmol/l (0.3-5.71) vs 1.4 nmol/l (0.9-4.0), thrombin-antithrombin complex (TAT) 4.0 μg/l (1.1-34.2) vs 5.2 μg/l (2.1-60.0), D-dimer (DD) 25 ng/ml (2-515) vs 44 ng/ml (2-160) or plasminogen activator inhibitor activity (PAI) 4.8 IU/ml (2.5-36.4) vs 4.4 IU/ml (2.5-13.4). Restenosis was observed in 13/60 patients (7/45-15% - aPL negative and 6/15-40% - aPL positive patients) who underwent angiographic tests after PTCA because of recurring angina or positive exercise test. Restenosis occurred after 2.2 months (0.5-3) in aPL positive patients and after 3.5 months (1-12.8) in aPL negative.

Original languageEnglish
Pages (from-to)141-148
Number of pages8
Issue number3
Publication statusPublished - 1998


  • Anticardiolipin antibodies
  • Antiphospholipid antibodies
  • Lupus anticoagulant
  • Percutaneous transluminal coronary angioplasty
  • Restenosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Antiphospholipid antibodies: A new risk factor for restenosis after percutaneous transluminal coronary angioplasty?'. Together they form a unique fingerprint.

Cite this